NANOFÁRMACOS

VolverVolver

Resultados 80 resultados LastUpdate Última actualización 20/01/2022 [09:45:00] pdf PDF xls XLS

Solicitudes publicadas en los últimos 15 días / Applications published in the last 15 days



Página1 de 4 nextPage   por página


VEHICLES FOR CONTROLLED DELIVERY OF DIFFERENT PHARMACEUTICAL AGENTS

NºPublicación: EP3939572A1 19/01/2022

Solicitante:

YALE UNIV INC [US]

JP_2022003102_A

Resumen de: WO2013155487A1

A "nanolipogel" is a delivery vehicle including one or more lipid layer surrounding a hydrogel core, which may include an absorbent such as a cyclodextrin or ion-exchange resin. Nanolipogels can be constructed so as to incorporate a variety of different chemical entities that can subsequently be released in a controlled fashion. These different incorporated chemical entities can differ dramatically with respect to size and composition. Nanolipogels have been constructed to contain co-encapsulated proteins as well as small hydrophobic drugs within the interior of the lipid bilayer. Agents incorporated within nanolipogels can be released into the milieu in a controlled fashion, for example, nanolipogels provide a means of achieving simultaneous sustained release of agents that differ widely in chemical composition and molecular weight. Additionally, nanolipogels can favorably modulate biodistribution.

traducir

BENZENE-1,3,5-TRICARBOXAMIDE DERIVATIVES AND USES THEREOF

NºPublicación: EP3939571A1 19/01/2022

Solicitante:

OHIO STATE INNOVATION FOUNDATION [US]

US_2018147166_A1

Resumen de: WO2016187531A1

The present invention relates to compounds, compositions, lipid-like nanoparticles, and methods for delivery of therapeutic, diagnostic, or prophylactic agents (for example, a polynucleotide).

traducir

HIV RNA VACCINES

NºPublicación: EP3938379A1 19/01/2022

Solicitante:

MODERNATX INC [US]
THE US SECRETARY DEPARTMENT OF HEALTH & HUMAN SERVICES [US]

WO_2020190750_A1

Resumen de: WO2020190750A1

Provided herein are methods and compositions for inducing in a subject a broad neutralizing antibody response to human immunodeficiency virus (HIV) infection.

traducir

PDRN Eye drops containing PDRN encapsulated chitosan nanoparticles and method for manufacturing the same

NºPublicación: EP3939565A1 19/01/2022

Solicitante:

ZERONE BIO INC [KR]

WO_2020184916_A1

Resumen de: KR102034982B1

The present specification relates to polymer nanoparticles in which nucleic acid fragments are encapsulated and a method for manufacturing the same. The polymer can be a mucoadhesive polymer, specifically chitosan, and the nucleic acid fragment can be PDRN. The polymer nanoparticle in which the nucleic acid fragments are encapsulated can be used as eye drops. The polymer nanoparticles in which the nucleic acid fragments are encapsulated can be combined with intraocular mucosa, thereby being able to exhibit an effect of slowly releasing nucleic acid fragments in the intraocular mucosa. In addition, the polymer nanoparticles in which the nucleic acid fragments are encapsulated can exhibit high efficiency at a low drug dosage in eyes, thereby exhibiting convenience or cost reduction effects for a patient.

traducir

REVERSIBLE COATING OF CHITOSAN-NUCLEIC ACID NANOPARTICLES AND METHODS OF THEIR USE

NºPublicación: EP3937982A1 19/01/2022

Solicitante:

ENGENE INC [CA]

CN_113874049_PA

Resumen de: WO2020183238A1

Chitosan-nucleic acid polyplex compositions containing a reversibly bound polymer coat comprising linear block copolymers with a polyanionic anchor region and at least one polyethylene glycol tail region are described herein. In some cases, the compositions exhibit improved stability and/or mucosal diffusion as compared to uncoated particles. In some cases, the reversibly bound polymer coat does not interfere with, or enhances, transfection of target cells or tissues as compared to uncoated particles.

traducir

REVERSIBLE COATING OF CHITOSAN-NUCLEIC ACID NANOPARTICLES AND METHODS OF THEIR USE

NºPublicación: EP3937981A1 19/01/2022

Solicitante:

ENGENE INC [CA]

CN_113874049_PA

Resumen de: WO2020183238A1

Chitosan-nucleic acid polyplex compositions containing a reversibly bound polymer coat comprising linear block copolymers with a polyanionic anchor region and at least one polyethylene glycol tail region are described herein. In some cases, the compositions exhibit improved stability and/or mucosal diffusion as compared to uncoated particles. In some cases, the reversibly bound polymer coat does not interfere with, or enhances, transfection of target cells or tissues as compared to uncoated particles.

traducir

STABILIZED SOLID NANOPARTICLE FORMULATIONS OF CANNABINOIDS AND CANNABINOID ANALOGS WITH REDUCED OSTWALD RIPENING FOR ORAL, INHALATION, NASAL AND PARENTERAL DRUG DELIVERY

NºPublicación: EP3937912A1 19/01/2022

Solicitante:

SELVARAJ ULAGARAJ [US]
WOODY DAVID L [US]
BOATRIGHT JOHN H [US]
WEN DONG [US]

WO_2020186246_A1

Resumen de: WO2020186246A1

The present invention provides pharmaceutical compositions comprising cannabinoids and/or cannabinoid analogs and processes for producing the same.

traducir

OPTICALLY HEAT-GENERATING COMPOSITE MATERIAL, NANOCLUSTER, SUBSTANCE DELIVERY CARRIER AND PHARMACEUTICAL COMPOSITION

NºPublicación: EP3939612A1 19/01/2022

Solicitante:

AIST [JP]
DAICEL CORP [JP]

KR_20210137106_PA

Resumen de: WO2020184271A1

The present invention provides an optically heat-generating composite material which is represented by formula (I) CNM-(Y1-R)n1 (wherein CNM represents a carbon nanomaterial; Y1 represents a divalent linking group; R represents a group derived from a fluorescent substance or a pigment; and n1 represents an integer of 1 or more).

traducir

NOVEL NANO-FORMULATION OF CANNABIDIOL (CBD) AND OTHER CANNABINOIDS FOR TREATMENT OF SKIN DISEASES

NºPublicación: EP3937915A1 19/01/2022

Solicitante:

MILANE MICHAEL [US]

CA_3133088_A1

Resumen de: WO2020186212A1

Compositions and methods are disclosed directed to nanoformulations of cannabidiol.

traducir

MODIFIED CARBON NANOMATERIAL, NANOCLUSTER, SUBSTANCE DELIVERY CARRIER AND PHARMACEUTICAL COMPOSITION

NºPublicación: EP3939936A1 19/01/2022

Solicitante:

AIST [JP]
DAICEL CORP [JP]

KR_20210136051_PA

Resumen de: WO2020184272A1

The present invention provides a nanocluster which is composed of self-assembled carbon nanomaterials that are modified with higher alkyl groups or higher alkenyl groups.

traducir

NANOMOLAR PEPTIDES AND DERIVATIVES TO DIFFERENTIALLY MODULATE EPHRIN RECEPTORS

NºPublicación: EP3937967A2 19/01/2022

Solicitante:

SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INST [US]

WO_2020186218_A2

Resumen de: WO2020186218A2

Disclosed herein are methods and compositions engineered to modulate EphA2, including novel peptides with unexpectedly high specificity and binding affinity. The compositions described herein can be attenuated to treat subjects suffering from diseases and/or conditions.

traducir

高载药效率纳米颗粒及其制备与应用

NºPublicación: CN113925841A 14/01/2022

Solicitante:

中国科学技术大学

Resumen de: CN113925841A

本发明涉及高载药效率纳米颗粒及其制备与应用。具体地,本发明涉及一种全新的基于自解聚聚合物纳米颗粒的抗肿瘤药物靶向递送体系。本发明设计的两亲性嵌段共聚物(BCP)P能够在水相中自组装成胶束纳米颗粒,具有疏水内核和亲水外壳结构。因此,疏水药物如拉帕醌可以物理包埋到纳米颗粒的疏水内核中。本发明的纳米颗粒能够较大提高拉帕醌的载药量(DLC)和载药效率(DLE)。其在正常细胞中保持稳定,药物无法释放从而毒性很小;而被肿瘤细胞上调的ROS触发后,破坏细胞的抗氧化系统,提升细胞的氧化压力杀死肿瘤细胞,治疗癌症。此外,在两亲性聚合物的末端修饰上靶向基团cRGD,纳米颗粒能够主动靶向富集在肿瘤组织中。

traducir

METHODS OF PREPARING LIPID NANOPARTICLES

NºPublicación: CN113939282A 14/01/2022

Solicitante:

摩登纳特斯有限公司

KR_20210135494_A

Resumen de: WO2020160397A1

The present disclosure provides methods of producing lipid nanoparticle (LNP) formulations and the produced LNP formulations thereof. The present disclosure also provides therapeutic and diagnostic uses related to the produced LNP formulations.

traducir

HIGH DENSITY LIPOPROTEIN NANOPARTICLES AND RNA TEMPLATED LIPOPROTEIN PARTICLES FOR OCULAR THERAPY

NºPublicación: CN113939278A 14/01/2022

Solicitante:

西北大学

AU_2020261414_A1

Resumen de: WO2020219833A1

Disclosed herein are nanostructures, compositions, and methods for treating ocular disorders, injuries, and infections using RNA complexed nanoparticles (e.g., RNA-templated lipoprotein particles, miRNA-high density lipoprotein particles). These nanostructures are contemplated in topical therapies.

traducir

ANHYDROUS ANTIMICROBIAL TOPICAL FORMULATIONS AND METHODS OF USE THEREOF

NºPublicación: US2022008461A1 13/01/2022

Solicitante:

NSC NANO SONO COOP LTD [IL]

Resumen de: US2022008461A1

Described herein are anhydrous antimicrobial topical formulations including metal nanoparticles and terpenes. Methods of use of the described formulations in wound treatment are also described.

traducir

Formulations and methods

NºPublicación: US2022008378A1 13/01/2022

Solicitante:

TESSMAR BELL JONATHAN [US]
CURRIER BYRON JOEL [US]

Resumen de: US2022008378A1

The present invention generally relates to formulations of and methods using one or more cannabis-derived compounds. In one aspect, the present invention provides a nanoemulsion. In addition to one or more cannabis-derived compounds (e.g., THC and/or CBD), the nanoemulsion typically includes at least one surfactant (e.g., Quillaja saponis), at least one encapsulator (e.g., modified food starch and/or maltodextrin), and at least one carrier (e.g., MCT coconut oil). Other suitable components such as one or more sweeteners (e.g., Xylitol) and/or one or more flow aids (e.g., Hydrophilic Fumed Silica having a Specific Surface Area (BET) between 175 m2/g and 225 m2/g) may be included. In certain cases, the nanoemulsion includes non-cannabis derived compounds such as caffeine and melatonin. The nanoemulsion typically has a Particle Size Distribution D50 of less than 500 nm, less than 400 nm, less than 300 nm, less than 200 nm or less than 100 nm.

traducir

TUMOR TREATMENT USING CYTOKINES AND CANCER DRUGS

NºPublicación: US2022008511A1 13/01/2022

Solicitante:

SMITH HENRY J [US]

Resumen de: US2022008511A1

This invention discloses a pharmaceutical composition for treating tumors wherein said pharmaceutical comprises a proinflammatory cytokine such as Tumor Necrosis Factor alpha (TNF-a) combined with one or more small molecule cancer drugs within the same liposome. The liposomes are sized to be below 250 nm in diameter to enable them to localize within the tumor due to the Enhanced Permeability and Retention (EPR) effect. This liposomal formulation will ensure that the proinflammatory cytokine and the cancer drug are localized together within the tumor and with less exposure to normal tissues. This invention also discloses that the safety and efficacy of said proinflammatory cytokine/drug liposomes could be further enhanced by coating the exterior of said liposomes with a tumor targeting agent.

traducir

PEGYLATED PEPTIDE AMPHIPHILE NANOFIBERS AND METHODS OF USE

NºPublicación: US2022008509A1 13/01/2022

Solicitante:

UNIV NORTHWESTERN [US]

Resumen de: US2022008509A1

Provided herein are peptide amphiphiles (PAs). In some embodiments, provided herein are PEGylated PAs (e.g. nonionic PAs). In some embodiments, the peptide amphiphiles are assembled into nanofibers. The nanofibers may further comprise a growth factor protein, which may bind to a growth factor binding sequence presented on the nonionic PA. In some embodiments, the nanofibers further comprise a charged peptide amphiphile. The charged peptide amphiphile may be bound to a growth factor protein. Further provided herein are methods of use of the peptide amphiphiles and compositions comprising the same, such as for regenerative therapy.

traducir

PROCESS FOR ENGINEERING TARGETED NANOPARTICLES

NºPublicación: US2022008350A1 13/01/2022

Solicitante:

UNIV OF NORTH TEXAS HEALTH SCIENCE CENTER [US]

WO_2020081642_PA

Resumen de: US2022008350A1

Certain embodiments are directed to methods for making programmable bioinspired nanoparticles (P-BiNP). Nanoparticles are coated with a cell membrane derived from a cell stimulated to express or overexpress a protein identified as being expressed in a target cell, forming a homotypic and organ targeted nanoparticle delivery vehicle.

traducir

COMPOUND DELIVERY SYSTEMS AND METHODS OF PRODUCTION

NºPublicación: US2022008348A1 13/01/2022

Solicitante:

GOLFETTO MICHAEL [US]

WO_2020097434_A1

Resumen de: US2022008348A1

A delivery composition including a plurality of first nanoparticle excipients each containing an active compound pharmaceutical agent and a plurality of second nanoparticle excipients each containing a modulating agent.

traducir

COMPOSITIONS AND METHODS OF TREATING MUSCLE ATROPHY AND MYOTONIC DYSTROPHY

NºPublicación: US2022008550A1 13/01/2022

Solicitante:

AVIDITY BIOSCIENCES INC [US]

US_2021187116_A1

Resumen de: US2022008550A1

Disclosed herein are polynucleic acid molecules, pharmaceutical compositions, and methods for treating muscle atrophy or myotonic dystrophy.

traducir

NOVEL NANOPARTICLES OF ANTIRETROVIRAL DRUGS, THEIR PREPARATION AND THEIR USE FOR THE TREATMENT OF VIRAL INFECTIONS

NºPublicación: US2022008554A1 13/01/2022

Solicitante:

CENTRE NAT RECH SCIENT [FR]
PASTEUR INSTITUT [FR]
UNIV PARIS SACLAY [FR]

WO_2020099547_A1

Resumen de: US2022008554A1

The present application relates to nanoparticles including an antiretroviral drug and chitosan and optionally one or more metal cation, their use for treating viral infections, their process of preparation and the pharmaceutical compositions including the same.

traducir

PREPARATION OF SOLID CYCLODEXTRIN COMPLEXES FOR OPHTHALMIC ACTIVE PHARMACEUTICAL INGREDIENT DELIVERY

NºPublicación: US2022008555A1 13/01/2022

Solicitante:

OCULIS SA [IS]

UA_124774_PA

Resumen de: US2022008555A1

The present disclosure relates to ophthalmic compositions containing solid complexes of active pharmaceutical ingredient and cyclodextrin, to their method of preparation and their uses. The compositions can include an active agent drug/cyclodextrin complex substantially dissolved in an aqueous eye drop vehicle. The ophthalmic composition is generally in the form of a microsuspension including an active agent complex having a diameter of less than about 100 μm.

traducir

IONIZABLE AMINE LIPIDS

NºPublicación: US2022009878A1 13/01/2022

Solicitante:

INTELLIA THERAPEUTICS INC [US]

JP_2022501412_A

Resumen de: US2022009878A1

The disclosure provides ionizable amine lipids and salts thereof (e.g., pharmaceutically acceptable salts thereof) useful for the delivery of biologically active agents, for example delivering biologically active agents to cells to prepare engineered cells. The ionizable amine lipids disclosed herein are useful as ionizable lipids in the formulation of lipid nanoparticle-based compositions.

traducir

PEPTIDE CONJUGATED PARTICLES

Nº publicación: US2022008523A1 13/01/2022

Solicitante:

UNIV NORTHWESTERN [US]

JP_2021193086_A

Resumen de: US2022008523A1

The present invention provides compositions comprising peptide-coupled biodegradable poly(lactide-co-glycolide) (PLG) particles. In particular, PLG particles are surface-functionalized to allow for coupling of peptide molecules to the surface of the particles (e.g., for use in eliciting induction of immunological tolerance).

traducir

Página1 de 4 nextPage por página

punteroimgVolver